SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    National Institute of Health [NIH]. NIH consensus statement on oral complications of cancer therapies: diagnosis, prevention, and treatment. NIH Consens Statement. 1989; 7: 111.
  • 2
    Peterson D. Research advances in oral mucositis. Curr Opin Oncol. 1999; 11: 261266.
  • 3
    Epstein J, Emerton S, Kolbinson D, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck. 1999; 21: 111.
  • 4
    Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47: 112.
  • 5
    Yuen K, Woo P, Hui C, et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant. 1998; 21: 11371143.
  • 6
    Wardley A, Jayson G, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000; 110: 292299.
  • 7
    Sonis S, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001; 19: 22012205.
  • 8
    Ruescher T, Sodeifi A, Scrivani S, Kaban L, Sonis S. The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998; 82: 22752281.
  • 9
    Lark R, McNeil S, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001; 33: 338343.
  • 10
    Elting L, Rubenstein E, Martin C, et al. Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001; 19: 11371146.
  • 11
    Elting L, Martin C, Cantor S, et al. The Bleeding Risk Index: a clinical prediction rule guiding the use of platelet growth factors and transfusions in cancer patients with lymphoma or solid tumors. Cancer. 2002; 94: 32523262.
  • 12
    Cancer Therapy Evaluation Program, National Cancer Institute. Common toxicity criteria. Version 2.0. Bethesda: National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services, 1999.
  • 13
    From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patients. Report of a consensus panel. J Infect Dis. 1990; 161: 397401.
  • 14
    Feld R. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement? Support Care Cancer. 1998; 6: 444448.
  • 15
    Beam TR Jr., Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti infective drug products. Clin Infect Dis. 1992; 15 Suppl 1: S5S32.
  • 16
    Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer. 1995; 31A: 20132022.
  • 17
    Elting L. Stratifications in clinical trials in febrile neutropenia. Support Care Cancer. 1998; 6: 457461.
  • 18
    Zubrod C, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative trial of nitrogen mustard and trimethylene thiophosphoramide. J Chronic Dis. 1960; 11: 733.
  • 19
    Harrell F, Lee K, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361387.
  • 20
    Savarese D, Hsieh C, Stewart F. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol. 1997; 15: 29812995.
  • 21
    Bellm L, Epstein J, Rose-Ped A, Martin P, Fuchs H. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000; 8: 3339.
  • 22
    Epstein J, Schubert M. Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999; 88: 273276.
  • 23
    McGuire D, Yeager K, Dudley W, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients. Cancer Nurs. 1998; 21: 385393.
  • 24
    McGuire D, Altomonte V, Peterson D, Wingard J, Jones R, Grochow L. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993; 20: 14931502.